StreetInsider.com News Articles

Form 144 Keros Therapeutics, Inc. Filed by: Farzan Nima

Thu, 04 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260604/26605784.html

Form 144 Keros Therapeutics, Inc. Filed by: Farzan Nima

Thu, 04 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260604/26605784.html

Form 144 Keros Therapeutics, Inc. Filed by: Knowles Julius

Thu, 04 Jun 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260604/26605715.html

Form 144 Keros Therapeutics, Inc. Filed by: Knowles Julius

Thu, 04 Jun 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260604/26605715.html

Form 144 Keros Therapeutics, Inc. Filed by: Seth Alpna

Thu, 04 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260604/26605669.html

Form 144 Keros Therapeutics, Inc. Filed by: Seth Alpna

Thu, 04 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260604/26605669.html

Form 8-K Keros Therapeutics, Inc. For: Jun 03

Wed, 03 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260603/26598670.html

Form 8-K Keros Therapeutics, Inc. For: Jun 03

Wed, 03 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260603/26598670.html

Form 8-K Keros Therapeutics, Inc. For: Jun 01

Mon, 01 Jun 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260601/26583354.html

Form 8-K Keros Therapeutics, Inc. For: Jun 01

Mon, 01 Jun 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260601/26583354.html

Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference

Mon, 01 Jun 2026 16:01:00 -0400

LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 p.m. Eastern time.

A live audio webcast of the fireside chat presentation

Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference

Mon, 01 Jun 2026 16:01:00 -0400

A live audio webcast of the fireside chat presentation

Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference

Mon, 01 Jun 2026 16:01:00 -0400

A live audio webcast of the fireside chat presentation

Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference

Mon, 01 Jun 2026 16:01:00 -0400

A live audio webcast of the fireside chat presentation

Form 4 Keros Therapeutics, Inc. For: May 15 Filed by: BIENAIME JEAN JACQUES

Tue, 19 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260519/26521333.html

Form 4 Keros Therapeutics, Inc. For: May 15 Filed by: BIENAIME JEAN JACQUES

Tue, 19 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260519/26521333.html

Form SCHEDULE 13G Keros Therapeutics, Inc. Filed by: Nantahala Capital Management, LLC

Fri, 15 May 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260515/26507173.html

Form SCHEDULE 13G Keros Therapeutics, Inc. Filed by: Nantahala Capital Management, LLC

Fri, 15 May 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260515/26507173.html

Keros Therapeutics (KROS) Misses Q1 EPS by 18c

Thu, 14 May 2026 08:30:12 -0400

Keros Therapeutics (NASDAQ: KROS) reported Q1 EPS of ($1.21), $0.18 worse than the analyst estimate of ($1.03). Revenue for the quarter came in at $370 thousand versus the consensus estimate of $1.69 million.

For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.

Form 8-K Keros Therapeutics, Inc. For: May 14

Thu, 14 May 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260514/26490366.html

Form 8-K Keros Therapeutics, Inc. For: May 14

Thu, 14 May 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260514/26490366.html

Form 10-Q Keros Therapeutics, Inc. For: Mar 31

Thu, 14 May 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260514/26490374.html

Form 10-Q Keros Therapeutics, Inc. For: Mar 31

Thu, 14 May 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260514/26490374.html

Keros Therapeutics Reports Recent First Quarter 2026 Financial Results

Thu, 14 May 2026 08:00:00 -0400

LEXINGTON, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today reported financial results for the quarter ended March 31, 2026.

“Continuing to progress our pipeline remains our top priority, setting the stage for future catalysts and growth opportunities,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer. “In addition, we are excited that

Keros Therapeutics Reports Recent First Quarter 2026 Financial Results

Thu, 14 May 2026 08:00:00 -0400